Sign in to view content

Port Delivery System With Ranibizumab: Key Outcomes From the Ladder Phase 2 Trial That Supported Archway Phase 3 Study Design

Arshad M. Khanani, MD, MA, FASRS

Video
Published 2019

Arshad M. Khanani, MD

AMD Neovascular Part II Symposium

Related

Aflibercept Monotherapy vs Initial Bevacizumab Followed by Aflibercept if Needed for Treatment of Center-Involved Diabetic Macular Edema
Chirag D. Jhaveri, MD, FASRS
Updates from the Field
2022
Evaluation of 8 mg Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration: Results from the Phase 2 CANDELA Study
W. Lloyd Clark, MD, FASRS
Updates from the Field
2022
Suprachoroidal CLS-TA Plus Aflibercept Compared With Aflibercept Monotherapy for DME: Results of a Phase 2 Trial
Michael S. Ip, MD
Annual Meeting Talks
2019

Category: AMD-Neovascular

See more